Cargando…

Identification of imatinib-resistant long non-coding RNAs in gastrointestinal stromal tumors

Long non-coding RNAs (lncRNAs) are an abundant RNA species that belong to the competing endogenous RNA network, which serves a critical role in the development, diagnosis and progression of diseases. Using chip technology, the current study analyzed the expression of lncRNAs in paired normal gastric...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Jingyi, Chen, Didi, Chen, Xiaolei, Sun, Xuecheng, Dong, Qiantong, Du, Zhou, Wang, Tingting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341907/ https://www.ncbi.nlm.nih.gov/pubmed/30675294 http://dx.doi.org/10.3892/ol.2018.9821

Ejemplares similares

Downregulation of lncRNA CCDC26 contributes to imatinib resistance in human gastrointestinal stromal tumors through IGF-1R upregulation
por: Yan, Jingyi, et al.
Publicado: (2019)

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors
por: Cao, Lei, et al.
Publicado: (2022)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Identification of long intergenic non-coding RNAs (lincRNAs) deregulated in gastrointestinal stromal tumors (GISTs)
por: Gyvyte, Ugne, et al.
Publicado: (2018)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs
por: Amirnasr, Azadeh, et al.
Publicado: (2019)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors
por: Takahashi, Tsuyoshi, et al.
Publicado: (2017)

A narrative review of imatinib-resistant gastrointestinal stromal tumors
por: Hayashi, Yujiro, et al.
Publicado: (2021)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
por: Hu, Xiangchen, et al.
Publicado: (2022)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Integrated analysis of long non-coding RNAs and mRNAs associated with malignant transformation of gastrointestinal stromal tumors
por: Yin, Xiaonan, et al.
Publicado: (2021)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
por: Sicklick, Jason K., et al.
Publicado: (2013)

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib
por: Moryoussef, Frédérick, et al.
Publicado: (2015)

Gastrointestinal Stromal Tumor With Chondrosarcomatous Dedifferentiation Following Imatinib Therapy
por: Koufopoulos, Nektarios, et al.
Publicado: (2021)

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor
por: Wang, Gang, et al.
Publicado: (2021)

Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib
por: Qu, Hui, et al.
Publicado: (2022)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Expression of stem cell factor in gastrointestinal stromal tumors: Implications for proliferation and imatinib resistance
por: HOU, XIAO-WEI, et al.
Publicado: (2013)

Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib
por: Gao, Xiaodong, et al.
Publicado: (2016)

RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor
por: Gao, Xiaodong, et al.
Publicado: (2016)

Imatinib-Resistant Gastrointestinal Stromal Tumor Presenting as a Large Abdominal Mass
por: Haider, Asim, et al.
Publicado: (2021)

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors
por: Masucci, Maria Teresa, et al.
Publicado: (2023)

A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment
por: Yin, Yuan, et al.
Publicado: (2016)

Long-term Results of Adjuvant Imatinib Treatment for Localized Gastrointestinal Stromal Tumors after Surgery
por: Aznab, Mozaffar, et al.
Publicado: (2018)

Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
por: Ichinose, Yuichi, et al.
Publicado: (2022)

Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance
por: Cao, Jie, et al.
Publicado: (2018)

Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway
por: Zheng, Song, et al.
Publicado: (2020)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
por: Annaberdyev, Shohrat, et al.
Publicado: (2009)

Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor
por: Quezada, Nicolás, et al.
Publicado: (2014)

Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib
por: Jiang, Xiaoyin, et al.
Publicado: (2015)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors
por: Coleman, Emily, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e8tq3e669bfrdo7gl6045dfshf